News Release

Experimental cancer vaccine shows promise in animal studies

IV administration improves tumor-fighting action, NIH researchers find

Peer-Reviewed Publication

NIH/National Institute of Allergy and Infectious Diseases

Colorized scanning electron micrograph of a T lymphocyte.

image: Colorized scanning electron micrograph of a T lymphocyte. view more 

Credit: NIAID

WHAT:
An experimental therapeutic cancer vaccine induced two distinct and desirable immune system responses that led to significant tumor regression in mice, report investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.  

The researchers found that intravenous (IV) administration of the vaccine boosted the number of cytotoxic T cells capable of infiltrating and attacking tumor cells and engaged the innate immune system by inducing type I interferon. The innate immune response modified the tumor microenvironment, counteracting suppressive forces that otherwise would tamp down T-cell action. Modification of the tumor microenvironment was not seen in mice that received the vaccine via needle injection into the skin (subcutaneous administration).

Dubbed “vax-innate” by the scientific team, the approach achieves an important goal in the quest for more effective immunotherapeutic vaccines for cancer. The study demonstrates that IV vaccine delivery enables and enhances T-cell immunity by overcoming tumor-induced immunosuppressive activity. The researchers say the candidate vaccine might also be given intravenously to people who have already received tumor-specific T cells as a therapy. It also could improve tumor control by increasing the number of T cells and altering the tumor microenvironment to make them function better, the researchers note. 

The experimental vaccine, SNAPvax, was designed by Robert Seder, M.D., and colleagues at the NIAID Vaccine Research Center (VRC) together with collaborators from Vaccitech North America, a clinical-stage biopharmaceutical company in Baltimore, Maryland. Vaccitech announced plans to advance the SNAPvax platform for use in treating human papilloma virus-associated cancer in 2023. 

ARTICLE:
F Baharom et al. Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironment. Cell DOI: 10.1016/j.cell.222.10.006 (2022).

WHO:
Dr. Robert Seder, chief, Cellular Immunology Section, VRC, NIAID, is available to comment.

CONTACT:
To schedule interviews, please contact NIAID News Office, (301) 402-1663, NIAIDNews@niaid.nih.gov.


NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov/.

NIH...Turning Discovery Into Health®


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.